The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.

Hims & Hers Health reported Q4 revenue of $481.14M, beating estimates of $470.31M, with EPS of $0.11, in line with expectations. The company’s Q4 revenue grew 69% YoY, with subscribers rising 45 ...

HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While ...

Hims & Hers once again delivered outstanding growth in Q4, with its revenue surging 95% to $481.1 million. That was well ahead of the revenue forecast of $465 million to $470 million it gave earlier.

Hims & Hers turned in tremendous revenue and profitability growth in the fourth quarter. The company also issued very robust guidance. However, it will stop selling semaglutide-based weight-loss ...

The stock is down 10.5% as 2 p.m. ET on Friday, while the stock is still up 224% in the last year. Here's why Hims & Hers ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its weight loss drug program. It is guiding for margin expansion and fast ...